On Friday, Shares of TiVo Inc. (NASDAQ:TIVO), gained 4.60% to $8.87.
TiVo Inc., introduced the TiVo BOLT, the most advanced television-viewing experience available.
The TiVo BOLT is all about speed, getting viewers to and through their content faster than ever. BOLT allows viewers to skip entire commercial breaks in a single bound at the press of a button. BOLT’s ability to skip entire commercial breaks of certain recorded shows with TiVo’s new SkipMode feature is a breakthrough that distinguishes BOLT from everything else.
TiVo Inc. provides television software services and cloud-based software-as-a-service solutions that enable to view video content through various screens. It offers whole-home solutions that comprise 4-Tuner and 6-Tuner digital video recorders (DVRs)/gateways, non-DVR IP set-top boxes (STBs), and software to enable streaming to application on third-party devices, such as iOS and Android mobile phones and tablets through features, such as What to Watch Now, OnePass, integrated search, access to broadband video content, and TiVo online/mobile scheduling.
Shares of New York REIT Inc (NYSE:NYRT), inclined 1.90% to $10.73, during its last trading session.
New York REIT, declared the initiation of a series of governance, planned and operational actions intended to enhance value for all shareholders and narrow the gap between net asset value (NAV) and the Company’s current common share price. These changes are the result of weeks of engagement with NYRT’s shareholders and careful consideration by the Company and its Board.
NYRT’s senior administration and Board of Directors unanimously endorsed the following actions:
- The Board designated Marc Rowan as a Director; The Board is conducting a search to identify additional independent director candidates, and plans to appoint two independent directors in the near future;
- The Company engaged the Eastdil Secured division of Wells Fargo Securities, a leading real estate investment banking group, as planned advisor to identify and consider potential planned transactions at the asset or entity level;
- The Company is releasing parties who took part in a previous planned transaction process from the standstill provisions of their non-disclosure agreements, enabling them to take part in any planned transactions at the asset or entity level;
- The Company continues to pursue its formerly declared plan to sell non-core, outer-borough assets; and
- The Company is in the process of implementing a joint venture arrangement with American Realty Capital New York City REIT, Inc. (“NYCR”), a non-traded REIT, eliminating competition for transactions between the two entities.
New York REIT, Inc. focuses on acquiring commercial real estate, in addition to acquiring properties or making other real estate investments that relate to office, retail, multi-family residential, industrial, and hotel property types located primarily in New York City.
Finally, Array Biopharma Inc (NASDAQ:ARRY), ended its last trade with 12.56% gain, and closed at $5.11.
Clinical trial results from Array BioPharma’s, wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology’s (ESMO) annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Array held a conference call to discuss these results and preliminary results from a colorectal cancer trial on Monday, September 28, 2015. Ron Squarer, Chief Executive Officer, and Victor Sandor, M.D., Chief Medical Officer, lead the call.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
